Vitamin D and Vascular Health in Children
Vitamin D and Vascular Function in Obese Children
調査の概要
詳細な説明
Our primary objective is to determine, in obese and overweight children aged 10 to 18 years with vitamin D deficiency (defined as serum 25-hydroxyvitamin D <20 ng/mL), the efficacy of enhanced vitamin D3 supplementation in improving vascular endothelial function, arterial stiffness, insulin sensitivity, and metabolic syndrome risk status; and to assess whether these effects are dose-dependent. As a secondary objective, we will examine the vitamin D supplementation-induced effect on adipokines and inflammatory markers relevant to CVD risk. In a double-masked, controlled trial, we will randomize 252 eligible children to receive either 600 IU (conventional supplementation), or 1000 IU or 2000 IU (enhanced supplementation) of vitamin D3 daily for 6 months.
In terms of reporting of results, the following pre-specified outcomes are included in the primary manuscript (PubMed PMID:31950134 -- see Reference section for citation details)
- Waist Circumference
- Serum High Density Lipoprotein (HDL) Cholesterol
- Serum Triglycerides
- Inflammatory markers (Plasma TNF-alpha, high-sensitivity C-reactive protein, and IL-6)
- Adiopkines (Plasma Leptin and Adiponectin)
Plasma nitric oxide metabolites were not measured.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15213
- Primary Care Center, Children's Hospital of Pittsburgh of UPMC
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Eligible subjects will be 10 to 18 years of age;
- obese or overweight (BMI ≥85th %tile);
- otherwise healthy, and
- have a serum 25(OH)D concentration <20 ng/mL
Children taking multivitamins should be able to hold off their multivitamins during the course of the study.
Exclusion Criteria:
Children will be excluded if they
- (a) have hepatic or renal disease, metabolic rickets, malabsorptive disorders, primary hyperparathyroidism, hyperthyroidism, or other chronic disorders that could affect vitamin D metabolism;
- (b) are receiving treatment with anticonvulsants, systemic glucocorticoids, pharmacologic doses of vitamin D (≥1000 IU of vitamin D2 or D3 daily), antihypertensives, vasoactive drugs, antilipidemics, metformin, antipsychotics, or other oral insulin regulators;
- (c) have cholelithiasis or urolithiasis;
- (d) have type 1 or type 2 diabetes; or
- (e) have a condition or underlying abnormality that could compromise the safety of the subject.
Post-menarchial girls with a positive pregnancy test at randomization, or subjects found during the screening phase to have hypercalcemia (serum calcium >10.8 mg/dL) or significant fasting hyperglycemia (fasting blood glucose ≥ 125 mg/dL) will also be excluded.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:Vitamin D3 2000 IU
Vitamin D3 2000 IU tablet once daily by mouth for 6 months
|
Tablet form
他の名前:
|
アクティブコンパレータ:Vitamin D3 1000 IU
Vitamin D3 1000 IU tablet by mouth once daily for 6 months
|
Tablet form
他の名前:
|
プラセボコンパレーター:Vitamin D3 600 IU
Vitamin D3 600 IU tablet by mouth once daily for 6 months
|
Tablet form
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Flow-mediated Dilation (FMD) Percentage
時間枠:6 months
|
Brachial artery flow-mediated dilation percentage is a measure of endothelial function.
FMD percentage calculation is based on baseline brachial artery diameter(brachialADbase) and change in brachial artery diameter (brachialADchange) during post-occlusive reactive hyperemia.
FMD% was determined using the formula (brachialADchange/brachialADbase) x 100.
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Pulse-wave Velocity (PWV)
時間枠:6 months
|
PWV is a measure of arterial stiffness.
Higher values of PWV indicate greater degree of arterial stiffness.
|
6 months
|
Augmentation Index at Heart Rate of 75 Beats/Min (AIx-75)
時間枠:6 months
|
AIx-75 is a measure of arterial stiffness. AIx was measured through radial arterial tonometry using SphygmoCor. Radial pulse waveform are analyzed through an automatic software function to determine aortic pulse waveform and aortic or central systolic (cSBP) and diastolic blood pressure (cDBP), and these measurements are further analyzed automatically to calculate AIx. AIx is a composite measure of the magnitude of wave reflection and arterial stiffness in all conduit arteries which affect the timing of the wave reflection. AIx = P2-P1/cSBP-cDBP, where P1 is the height of the incident pressure wave form during systole, P2 is the height of the reflected wave added to the incident wave, cSBP is the aortic systolic BP, and cDBP is the aortic diastolic BP. AIx adjusted to heart rate of 75 beats/min (AIx-75) is a validated index of arterial stiffness, with higher values indicating higher degree of arterial stiffness. |
6 months
|
Central Systolic Blood Pressure
時間枠:6 months
|
a measure of cardiometabolic health
|
6 months
|
Central Diastolic Blood Pressure
時間枠:6 months
|
a measure of cardiometabolic health
|
6 months
|
Systemic Systolic Blood Pressure
時間枠:6 months
|
a measure of cardiometabolic health
|
6 months
|
Systemic Diastolic Blood Pressure
時間枠:6 months
|
a measure of cardiometabolic health
|
6 months
|
Fasting Blood Glucose
時間枠:6 months
|
a measure of cardiometabolic health
|
6 months
|
1/Fasting Insulin Ratio
時間枠:6 months
|
1/fasting insulin ratio is a measure of insulin sensitivity.
Increases in 1/fasting insulin ratio indicate improvements in insulin sensitivity.
|
6 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Body Mass Index (BMI)
時間枠:6 months
|
a surrogate measure of adiposity
|
6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Kumaravel Rajakumar, MD, MS、University of Pittsburgh, Children's Hospital of Pittsburgh of UPMC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Vitamin D3の臨床試験
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, Denmark完了
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute of Child... と他の協力者完了
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)完了